查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1612664

乳癌诊断市场：按技术、按癌症类型、按组成部分、按诊断类型、按最终用户划分 - 全球预测 2025-2030

Breast Cancer Diagnostics Market by Technique (Imaging, Molecular Testing, Tissue Biopsy Tests), Cancer Type (BRCA Breast Cancer, EGFR Mutation Test Breast Cancer, ER & PR Breast Cancer), Component, Diagnostic Type, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年乳癌诊断市值为65.4亿美元，预计到2024年将达到70.4亿美元，复合年增长率为7.79%，到2030年将达到110.6亿美元。

乳癌诊断市场是肿瘤学的重要组成部分，其特点是用于乳癌检测和诊断的技术和产品。这包括乳房X光摄影、超音波、MRI、切片检查、先进的分子诊断等等。这些诊断对于早期发现疾病并显着改善患者的治疗效果至关重要。应用范围涵盖医院、诊断中心和研究机构，满足筛检和诊断需求。透过早期准确的诊断，这些工具在治疗计划和患者管理中发挥着至关重要的作用，极大地影响了医疗保健。

主要市场统计
基准年[2023] 65.4亿美元
预计年份 [2024] 70.4亿美元
预测年份 [2030] 110.6亿美元
复合年增长率（%） 7.79%

市场成长受到多种因素的推动，包括全球乳癌发生率上升、诊断技术的进步以及早期检测意识的提高。此外，支持医疗保健政策和改善新兴市场的医疗保健基础设施将推动成长。诊断成像、液态切片和基因检测领域的人工智慧和机器学习等技术创新正在创造新的机会。对个人化医疗的投资和不断增长的数位医疗采用将进一步扩大市场格局。然而，市场限制包括先进诊断设备的高成本、监管障碍以及影响诊断可靠性和患者信任的误报和漏报风险。

挑战包括获得医疗保健的地区差异，这影响了诊断工具的可用性和实施，以及公共卫生系统的预算限制，阻碍了新技术的引入。需要创新和研究的领域包括开发具有成本效益的非侵入性诊断测试以及增强具有更高灵敏度和特异性的诊断影像技术。遗传和生物标记研究的进一步进展也可以带来显着的好处。为了抓住新的商机，相关人员应专注于伙伴关係策略，加强研发能力，并利用巨量资料分析来提高诊断的准确性和效率。市场正在动态发展，随着技术创新的不断变革，存在着巨大的成长空间。

市场动态：揭示快速发展的乳癌诊断市场的关键市场洞察

供需的动态交互作用正在改变乳癌诊断市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球乳癌发生率不断上升
    • 乳癌诊断的有利报销框架
    • 全球乳癌筛检计画的增加
  • 市场限制因素
    • 与乳癌诊断测试相关的高成本
  • 市场机会
    • 将人工智慧 (AI) 和机器学习 (ML) 整合到乳癌诊断中
    • 癌症诊断技术的持续研发活动
  • 市场挑战
    • 缺乏熟练且训练有素的专业人员

波特五力：开拓乳癌诊断市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对乳癌诊断市场的影响

外部宏观环境因素在塑造乳癌诊断市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解乳癌诊断药物市场的竞争状况

乳癌诊断市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

乳癌诊断市场中的 FPNV 定位矩阵供应商绩效评估

FPNV定位矩阵是评估乳癌诊断市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘乳癌诊断市场的成功之路

乳癌诊断市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球乳癌发生率上升
      • 乳癌诊断的有利报销框架
      • 世界各地乳癌筛检计画不断增加
    • 抑制因素
      • 乳癌诊断测试的高成本
    • 机会
      • 将人工智慧 (AI) 和机器学习 (ML) 整合到乳癌诊断中
      • 癌症诊断技术的持续研发活动
    • 任务
      • 缺乏熟练且训练有素的专业人员
  • 市场区隔分析
    • 技术：分子生物学和基因组生物学的进步将提高分子检测的普及率
    • 癌症类型：BRCA乳癌是一种遗传性乳癌
    • 诊断类型：非电离成像技术在乳癌诊断的应用进展
    • 最终使用者：乳癌诊断药物在诊断实验室的采用率很高
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章乳癌诊断市场：依技术分类

  • 影像
    • 模拟乳房X光摄影
    • 乳房超音波系统
    • 数位乳房摄影
    • 乳房X光检查
    • 核磁共振扫描
    • PET/ 电脑断层扫描
  • 分子检测
  • 组织切片检查测试

第七章按癌症类型分類的乳癌诊断药物市场

  • BRCA 乳癌
  • EGFR突变检测乳癌
  • ER & PR 乳癌
  • HER2乳癌

第八章乳癌诊断市场：依组成部分

  • 消耗品
    • 抗体
    • 试剂套件和试剂
    • 探测
  • 装置
    • 切片检查仪器
    • 影像设备
    • 病理学设备

第九章按诊断类型分類的乳癌诊断药物市场

  • 电离乳房摄影技术
  • 非电离成像技术

第 10 章乳癌诊断市场：依最终用户分类

  • 诊断实验室
  • 医院及门诊手术中心
  • 研究/学术机构

第十一章 北美和南美乳癌诊断药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区乳癌诊断药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲乳癌诊断药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Solis Mammography 宣布收购 Carolina Breast Imaging
    • 强生 Impact Ventures 投资 Mamotest，以改善拉丁美洲乳癌患者获得治疗的机会
    • Sysmex Europe 将透过与 Cerca Biotech 签订的欧洲分销协议销售先进的乳癌诊断测试 MammaTyper。
  • 战略分析和建议

公司名单

  • 4D Path Inc.
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • AstraZeneca PLC
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biocept, Inc.
  • Biodesix
  • Cardinal Health
  • Danaher Corporation
  • Epigenomics AG
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fluxion Biosciences Inc. by Cell Microsystems
  • FUJIFILM Holdings Corporation
  • General Electric Company
  • Hologic, Inc.
  • Illumina, Inc.
  • Koninklijke Philips NV
  • NanoString Technologies, Inc.
  • NeoGenomics Laboratories
  • Olea Medical
  • OncoGenomX
  • Paragon Biosciences LLC by Catalent, Inc.
  • Provista Diagnostics, Inc. by Todos Medical
  • Quest Diagnostics Incorporated
  • Siemens Healthcare Private Limited
  • Thermo Fisher Scientific Inc.
Product Code: MRR-A26E0E57405A

The Breast Cancer Diagnostics Market was valued at USD 6.54 billion in 2023, expected to reach USD 7.04 billion in 2024, and is projected to grow at a CAGR of 7.79%, to USD 11.06 billion by 2030.

The Breast Cancer Diagnostics market is a critical component of oncology, characterized by techniques and products used for the detection and diagnosis of breast cancer. This includes mammography, ultrasound, MRI, biopsy, and advanced molecular diagnostics. These diagnostics are essential for early disease detection, improving patient outcomes significantly. The application spans hospitals, diagnostic centers, and research institutes, addressing both screening and diagnostic needs. Through early and accurate diagnosis, these tools play a pivotal role in treatment planning and patient management, thereby carrying significant healthcare implications.

KEY MARKET STATISTICS
Base Year [2023] USD 6.54 billion
Estimated Year [2024] USD 7.04 billion
Forecast Year [2030] USD 11.06 billion
CAGR (%) 7.79%

Market growth is driven by several factors, including the rising prevalence of breast cancer globally, advancements in diagnostic technology, and increased awareness about early detection. Additionally, supportive healthcare policies and improving healthcare infrastructure across emerging markets foster growth. Technological innovations such as AI and machine learning in imaging, liquid biopsies, and genetic testing are presenting new opportunities. Investments in personalized medicine and growing adoption of digital health further expand market prospects. However, market limitations include high costs of advanced diagnostic devices, regulatory hurdles, and the risk of false positives and negatives, which can affect diagnostic credibility and patient trust.

Challenging factors include the variability in healthcare access across regions, influencing the availability and adoption of diagnostic tools, and potential resistance to adopting new technologies due to budget constraints in public healthcare systems. Areas ripe for innovation and research include the development of cost-effective, non-invasive diagnostic tests, and enhanced imaging techniques with higher sensitivity and specificity. Further exploration into genetic and biomarker research could also yield substantial benefits. To capitalize on emerging opportunities, stakeholders should focus on partnership strategies, enhancing R&D capabilities, and leveraging big data analytics to improve diagnostic accuracy and efficiency. The market is dynamic and evolving, with substantial room for growth as innovations continue to transform breast cancer diagnostics.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Breast Cancer Diagnostics Market

The Breast Cancer Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidence of breast cancer globally
    • Favorable reimbursement framework for breast cancer diagnosis
    • Growing number of breast cancer screening programs worldwide
  • Market Restraints
    • High cost associated with breast cancer diagnostic tests
  • Market Opportunities
    • Integration of artificial intelligence (AI) and machine learning (ML) in breast cancer diagnostic
    • Ongoing research and development activities in cancer diagnostic techniques
  • Market Challenges
    • Dearth of the skilled and trained professionals

Porter's Five Forces: A Strategic Tool for Navigating the Breast Cancer Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Breast Cancer Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Breast Cancer Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Breast Cancer Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Breast Cancer Diagnostics Market

A detailed market share analysis in the Breast Cancer Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Breast Cancer Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Breast Cancer Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Breast Cancer Diagnostics Market

A strategic analysis of the Breast Cancer Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Breast Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include 4D Path Inc., Abbott Laboratories, Agilent Technologies, Inc., AstraZeneca PLC, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biocept, Inc., Biodesix, Cardinal Health, Danaher Corporation, Epigenomics AG, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Fluxion Biosciences Inc. by Cell Microsystems, FUJIFILM Holdings Corporation, General Electric Company, Hologic, Inc., Illumina, Inc., Koninklijke Philips N.V., NanoString Technologies, Inc., NeoGenomics Laboratories, Olea Medical, OncoGenomX, Paragon Biosciences LLC by Catalent, Inc., Provista Diagnostics, Inc. by Todos Medical, Quest Diagnostics Incorporated, Siemens Healthcare Private Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Breast Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technique, market is studied across Imaging, Molecular Testing, and Tissue Biopsy Tests. The Imaging is further studied across Analog Mammography, Breast Ultrasound System, Digital Mammography, Mammography, MRI Scan, and PET/CT Scan.
  • Based on Cancer Type, market is studied across BRCA Breast Cancer, EGFR Mutation Test Breast Cancer, ER & PR Breast Cancer, and HER 2 Breast Cancer.
  • Based on Component, market is studied across Consumables and Instruments. The Consumables is further studied across Antibodies, Kits & Reagents, and Probes. The Instruments is further studied across Biopsy Instruments, Imaging Instruments, and Pathology-Based Instruments.
  • Based on Diagnostic Type, market is studied across Ionizing Breast Imaging Technologies and Non-Ionizing Imaging Technologies.
  • Based on End-User, market is studied across Diagnostic Laboratories, Hospitals & Ambulatory Surgery Center, and Research & Academic Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidence of breast cancer globally
      • 5.1.1.2. Favorable reimbursement framework for breast cancer diagnosis
      • 5.1.1.3. Growing number of breast cancer screening programs worldwide
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with breast cancer diagnostic tests
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of artificial intelligence (AI) and machine learning (ML) in breast cancer diagnostic
      • 5.1.3.2. Ongoing research and development activities in cancer diagnostic techniques
    • 5.1.4. Challenges
      • 5.1.4.1. Dearth of the skilled and trained professionals
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technique: Advancements in molecular and genomic biology advancing the penetration of molecular testing
    • 5.2.2. Cancer Type: BRCA breast cancer is highly implicated as a hereditary breast cancer
    • 5.2.3. Diagnostic Type: Advancing applications of non-ionizing imaging technologies for breast cancer diagnostics
    • 5.2.4. End-User: High adoption of breast cancer diagnostics in the diagnostic laboratories
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Breast Cancer Diagnostics Market, by Technique

  • 6.1. Introduction
  • 6.2. Imaging
    • 6.2.1. Analog Mammography
    • 6.2.2. Breast Ultrasound System
    • 6.2.3. Digital Mammography
    • 6.2.4. Mammography
    • 6.2.5. MRI Scan
    • 6.2.6. PET/CT Scan
  • 6.3. Molecular Testing
  • 6.4. Tissue Biopsy Tests

7. Breast Cancer Diagnostics Market, by Cancer Type

  • 7.1. Introduction
  • 7.2. BRCA Breast Cancer
  • 7.3. EGFR Mutation Test Breast Cancer
  • 7.4. ER & PR Breast Cancer
  • 7.5. HER 2 Breast Cancer

8. Breast Cancer Diagnostics Market, by Component

  • 8.1. Introduction
  • 8.2. Consumables
    • 8.2.1. Antibodies
    • 8.2.2. Kits & Reagents
    • 8.2.3. Probes
  • 8.3. Instruments
    • 8.3.1. Biopsy Instruments
    • 8.3.2. Imaging Instruments
    • 8.3.3. Pathology-Based Instruments

9. Breast Cancer Diagnostics Market, by Diagnostic Type

  • 9.1. Introduction
  • 9.2. Ionizing Breast Imaging Technologies
  • 9.3. Non-Ionizing Imaging Technologies

10. Breast Cancer Diagnostics Market, by End-User

  • 10.1. Introduction
  • 10.2. Diagnostic Laboratories
  • 10.3. Hospitals & Ambulatory Surgery Center
  • 10.4. Research & Academic Institutes

11. Americas Breast Cancer Diagnostics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Breast Cancer Diagnostics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Breast Cancer Diagnostics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Solis Mammography Announces Acquisition of Carolina Breast Imaging
    • 14.3.2. Johnson & Johnson Impact Ventures Invests in Mamotest to Improve Access to Care for Breast Cancer Patients in Latin America
    • 14.3.3. Sysmex Europe Distributes MammaTyper, an Advanced Breast Cancer Diagnostic Assay, Through The European Distribution Agreement With Cerca Biotech
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 4D Path Inc.
  • 2. Abbott Laboratories
  • 3. Agilent Technologies, Inc.
  • 4. AstraZeneca PLC
  • 5. Becton, Dickinson and Company
  • 6. Bio-Rad Laboratories, Inc.
  • 7. Biocept, Inc.
  • 8. Biodesix
  • 9. Cardinal Health
  • 10. Danaher Corporation
  • 11. Epigenomics AG
  • 12. Exact Sciences Corporation
  • 13. F. Hoffmann-La Roche Ltd.
  • 14. Fluxion Biosciences Inc. by Cell Microsystems
  • 15. FUJIFILM Holdings Corporation
  • 16. General Electric Company
  • 17. Hologic, Inc.
  • 18. Illumina, Inc.
  • 19. Koninklijke Philips N.V.
  • 20. NanoString Technologies, Inc.
  • 21. NeoGenomics Laboratories
  • 22. Olea Medical
  • 23. OncoGenomX
  • 24. Paragon Biosciences LLC by Catalent, Inc.
  • 25. Provista Diagnostics, Inc. by Todos Medical
  • 26. Quest Diagnostics Incorporated
  • 27. Siemens Healthcare Private Limited
  • 28. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. BREAST CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. BREAST CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. BREAST CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. BREAST CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BREAST CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BREAST CANCER DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ANALOG MAMMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BREAST ULTRASOUND SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL MAMMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MRI SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PET/CT SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BRCA BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY EGFR MUTATION TEST BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ER & PR BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HER 2 BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PROBES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY-BASED INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NON-IONIZING IMAGING TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & AMBULATORY SURGERY CENTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 137. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 145. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 161. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 177. TAIWAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TAIWAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 185. THAILAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. THAILAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 193. VIETNAM BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. VIETNAM BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 210. DENMARK BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. DENMARK BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 218. EGYPT BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. EGYPT BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 226. FINLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. FINLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 234. FRANCE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. FRANCE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 242. GERMANY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. GERMANY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 250. ISRAEL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. ISRAEL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 258. ITALY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. ITALY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 266. NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 274. NIGERIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. NIGERIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 282. NORWAY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. NORWAY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 285. POLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 286. POLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 290. POLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 292. POLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 293. QATAR BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 294. QATAR BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 298. QATAR BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 300. QATAR BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 301. RUSSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 302. RUSSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 306. RUSSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. RUSSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 310. SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 312. SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 314. SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 316. SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 318. SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 322. SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 324. SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 325. SPAIN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 326. SPAIN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 327. SPAIN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 328. SPAIN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 329. SPAIN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 330. SPAIN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 331. SPAIN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 332. SPAI